Semi-quantitative FDG parameters predict survival in multiple myeloma patients without autologous stem cell transplantation

Table 2 Cox regression analysis for OS in the entire study population (n = 227)

Variable	Categories	Univariate			Multivariate
Variable	Categories	HR (95% CI)	P	Log-rank	HR (95% CI)	P
Sex	Male	1.12 (0.71–1.79)	0.629	0.629
Age	57	1.00		0.010
	57–66	1.19 (0.63–2.25)	0.586		1.04 (0.52–2.05)	0.920
	≥ 66	2.20 (1.23–3.94)	0.008		0.69 (0.30–1.57)	0.372
Age (continuous)	Per 1 year	1.04 (1.01–1.06)	0.004
Chemotherapy regimen	VTD	1.00		0.017
	VMP	2.69 (1.43–5.06)	0.002		0.96 (0.42–2.17)	0.917
	Other 3-drugs*	1.93 (0.89–4.16)	0.094		2.22 (0.98–5.01)	0.056
	Miscellaneous	2.03 (1.07–3.86)	0.031		1.33 (0.62–2.85)	0.457
Radiotherapy	Yes	1.11 (0.57–2.17)	0.752	0.751
ASCT	Yes	0.34 (0.22–0.56)	< 0.001	< 0.001	0.23 (0.11–0.50)	< 0.001
R-ISS stage	I	1.00		< 0.001
	II	2.34 (1.29–4.25)	0.005		2.06 (1.11–3.79)	0.021
	III	4.19 (2.12–8.26)	< 0.001		4.01 (1.98–8.13)	< 0.001
Hypercalcemia	Yes	0.59 (0.25–1.35)	0.210	0.204
Renal insufficiency	Yes	1.13 (0.66–1.90)	0.682	0.682
Anemia	Yes	1.38 (0.87–2.19)	0.173	0.171
Bone lesions positive	Yes	1.14 (0.57–2.29)	0.717	0.715
Extramedullary disease	Yes	1.52 (0.87–2.68)	0.152	0.149

OS: overall survival; HR: hazard ratio; CI: confidence interval; VTD: bortezomib, thalidomide, dexamethasone; VMP: bortezomib, melphalan, prednisone; ASCT: autologous stem cell transplantation; R-ISS: Revised Multiple Myeloma International Staging System. *Three-drug regimens other than VTD or VMP.

ISSN: 1470-7330